Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003518 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
A Phase 2 study of Ovarian Cancer and Testicular Germ Cell Tumor, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 19
- Study locations
NCT00003518: Completed Phase 2 study of Ovarian Cancer and Testicular Germ Cell Tumor, sponsored by Eastern Cooperative Oncology Group.
NCT00003518 is a Phase 2 study of Ovarian Cancer and Testicular Germ Cell Tumor that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 44 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003518, a Phase 2 study of Ovarian Cancer and Testicular Germ Cell Tumor, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 19
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory metastatic germ cell tumors that have not responded to surgery or chemotherapy.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG gemcitabine hydrochloride
Study Locations (19)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- Veterans Affairs Medical Center - Chicago (Lakeside) - Chicago
- CCOP - Carle Cancer Center - Urbana
New Jersey
- Hackensack University Medical Center - Hackensack
- Kimball Medical Center - Lakewood
- Morristown Memorial Hospital - Morristown
Indiana
- Indiana University Cancer Center - Indianapolis
- Veterans Affairs Medical Center - Indianapolis (Roudebush) - Indianapolis
Colorado
- CCOP - Colorado Cancer Research Program, Inc. - Denver
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
Louisiana
- CCOP - Ochsner - New Orleans
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- CCOP - Kalamazoo - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 1999-01-25 |
| Phase | Phase 2 |
What the finished NCT00003518 record still lists
NCT00003518 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00003518 lists 19 locations in 14 states (Illinois, New Jersey, Indiana).
Frequently Asked Questions
What is clinical trial NCT00003518 about?
NCT00003518 is a clinical study titled "Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory meta...
What is the current status of trial NCT00003518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 1999-01-25.
What conditions does trial NCT00003518 study?
This clinical trial studies the following conditions: Ovarian Cancer, Testicular Germ Cell Tumor.
What interventions are being tested in trial NCT00003518?
The interventions under investigation include: paclitaxel (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003518?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003518 being conducted?
This trial has 19 study locations across Colorado, Illinois, Indiana, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003518's enrollment target sits among peer trials
44 221st of 322 higher than 102 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI